Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Dimensional Fund Advisors LP reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 70.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,666 shares of the biotechnology company’s stock after selling 86,214 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Arrowhead Pharmaceuticals were worth $671,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $38,000. Van ECK Associates Corp grew its stake in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV grew its stake in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $190,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $205,000. 62.61% of the stock is owned by institutional investors.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 133,333 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the sale, the chief executive officer now directly owns 3,773,802 shares of the company’s stock, valued at $64,230,110.04. The trade was a 3.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 275,880 shares of company stock worth $4,034,037. 4.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ARWR shares. StockNews.com upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Citigroup dropped their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Chardan Capital reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.13.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $15.71 on Friday. The company has a 50-day simple moving average of $13.30 and a two-hundred day simple moving average of $17.80. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41. The firm has a market capitalization of $2.17 billion, a PE ratio of -3.04 and a beta of 0.89. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period last year, the business earned ($1.02) EPS. On average, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.